BPC-157 + TB-500 + GHK-Cu Advanced Recovery Protocol
Three-peptide advanced soft tissue + dermal remodelling research stack. Adds GHK-Cu copper peptide to the canonical BPC-157/TB-500 base for collagen-I:III ratio improvement.
This three-peptide stack extends the canonical BPC-157 + TB-500 healing protocol with GHK-Cu (glycyl-histidyl-lysine, copper-bound tripeptide) for advanced extracellular-matrix remodelling research.
Why three peptides?
Wound healing has three temporally separated phases — angiogenesis, cellular migration, and matrix remodelling. The canonical two-peptide stack covers angiogenesis (BPC-157) and progenitor cell recruitment (TB-500), but leaves matrix remodelling to the animal's intrinsic GHK-Cu pool. Adding exogenous GHK-Cu accelerates the final phase, producing measurable improvements in collagen-I to collagen-III ratio in published rodent studies.
Mechanism of action
GHK-Cu (added compound) — mechanism of action
GHK-Cu is a copper-bound tripeptide (glycyl-histidyl-lysine) present endogenously in plasma. Its concentration declines with age. In published research:
- Activates fibroblast collagen and elastin synthesis at the gene-expression level.
- Up-regulates anti-oxidant enzymes (SOD2, catalase) in dermal tissue.
- Modulates matrix metalloproteinase (MMP-2, MMP-9) activity, favouring remodelling over degradation.
- Stimulates copper-dependent enzymes in connective tissue, including lysyl oxidase (the cross-linking enzyme essential for collagen tensile strength).
For BPC-157 and TB-500 mechanism details, see the canonical BPC-157 + TB-500 stack page.
Full research protocol — dosing table
| Peptide | Dose | Frequency | Timing | Cycle length |
|---|---|---|---|---|
| BPC-157 | 500 µg | Twice daily SC | AM + PM | 8 weeks |
| TB-500 | 2.5 mg | Twice weekly SC (load 4 wks) → 2 mg weekly | Mon + Thu | 8 weeks |
| GHK-Cu | 1–2 mg | Daily SC | Evening, rotate sites | 6–8 weeks |
Weekly research timeline
| Peptide | Wk 1 | Wk 2 | Wk 3 | Wk 4 | Wk 5 | Wk 6 | Wk 7 | Wk 8 |
|---|---|---|---|---|---|---|---|---|
| BPC-157 | 500 µg BID | 500 µg BID | 500 µg BID | 500 µg BID | 500 µg BID | 500 µg BID | 250 µg BID | 250 µg BID |
| TB-500 | 2.5 mg 2x | 2.5 mg 2x | 2.5 mg 2x | 2.5 mg 2x | 2.0 mg 1x | 2.0 mg 1x | 2.0 mg 1x | 2.0 mg 1x |
| GHK-Cu | 1 mg | 2 mg | 2 mg | 2 mg | 2 mg | 2 mg | 1 mg | 1 mg |
Routes: SC = subcutaneous · IM = intramuscular · IN = intranasal · Oral · Topical.
Safety profile & regulatory note
Where to source these research peptides
Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.